Market Place
Sourcing Support
180 Life Science Retains Senior Consultant, Begins Tech Integration
31 Oct 2024 //
ACCESSWIRE
180 Life Sciences Appoints Jay Goodman to Board of Directors
29 Oct 2024 //
ACCESSWIRE
180 Life Sciences Interim CEO Updates Stockholders On Gaming Tech
16 Oct 2024 //
ACCESSWIRE
180 Life Sciences Regains Nasdaq Compliance And Expands Globally
09 Oct 2024 //
ACCESSWIRE
180 Life Sciences Corp. - Corporate Updates
03 Oct 2024 //
ACCESSWIRE
180 Life Sciences Appoints Omar Jimenez As CFO
12 Sep 2024 //
GLOBENEWSWIRE
180 Life Sciences Reports Positive Results For New CBD Formulation
30 Jul 2024 //
GLOBENEWSWIRE
180 Life Sciences Gets Nasdaq Extension To Regain Compliance
23 Jul 2024 //
GLOBENEWSWIRE
180 Life Sciences Granted Nasdaq Extension To Regain Compliance
02 Jul 2024 //
GLOBENEWSWIRE
180 Life Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
14 Mar 2024 //
GLOBENEWSWIRE
180 Life Sciences Announces Review of Strategic Alternatives
28 Nov 2023 //
GLOBENEWSWIRE
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
14 Aug 2023 //
GLOBENEWSWIRE
180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering
10 Aug 2023 //
GLOBENEWSWIRE
180 Life Announces an Agreement for a Clinical Pharmacology Study Testing
07 Aug 2023 //
GLOBENEWSWIRE
180 Life Provides Update on Approval Process for Dupuytren`s Disease Treatment
03 Aug 2023 //
GLOBENEWSWIRE
180 Life Announces the Filing of a Patent Describing the Combination of CBD With GLP-1 Agonists
31 Jul 2023 //
GLOBENEWSWIRE
180 Life Sciences Announces Closing of $3 Million Registered Direct Offering
10 Apr 2023 //
GLOBENEWSWIRE
180 Life Sciences Announces $3 Million Registered Direct Offering
05 Apr 2023 //
GLOBENEWSWIRE
180 Life Sciences Announces Presentation at the Gordon Conference
27 Feb 2023 //
GLOBENEWSWIRE
180 Life Announces Allowance of Claims for a US Patent for Dupuytren Disease
23 Feb 2023 //
GLOBENEWSWIRE
180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial
22 Feb 2023 //
GLOBENEWSWIRE
180 Life Announces Publication of a Review on Treatments for Dupuytren`s Disease
25 Jan 2023 //
GLOBENEWSWIRE
180 Life Engages Kinexum for Assistance in Applying for Marketing Authorisation
17 Jan 2023 //
GLOBENEWSWIRE
180 Life Sciences Corp. Announces Closing of $6 M Registered Direct Offering
23 Dec 2022 //
GLOBENEWSWIRE
180 Life Sciences Announces 1-for 20 Reverse Stock Split
16 Dec 2022 //
GLOBENEWSWIRE
180 Life Sciences Provides Update on Progress To Seek Med & Healthcare Products
30 Nov 2022 //
GLOBENEWSWIRE
180 Life Sciences to Participate in A.G.P.’s Virtual Biotech Conference
21 Nov 2022 //
GLOBENEWSWIRE
180 Life with University of Oxford Announce Enrollment in Anti-TNF Trial
22 Aug 2022 //
GLOBENEWSWIRE
University of Oxford Awarded Grant From the NIH and Care Research in the U.K.
27 Jul 2022 //
GLOBENEWSWIRE
180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering
18 Jul 2022 //
GLOBENEWSWIRE
180 Life Sciences Corp. Issues Letter to Stockholders
22 Jun 2022 //
GLOBENEWSWIRE
180 Life Sciences Provides Update from U.S. & UK Regulatory Authorities
14 Jun 2022 //
GLOBENEWSWIRE
180 Life Sciences Begins Consultations with UK and US Regulatory Authorities
31 May 2022 //
GLOBENEWSWIRE
180 Life Sciences, University of Oxford to publish PIIb Dupuytren`s Study Result
29 Apr 2022 //
GLOBENEWSWIRE
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
31 Jan 2022 //
GLOBENEWSWIRE
180 Life Sciences Corp. Publishes Pre-Clinical Study Report on Effects of CBG
26 Oct 2021 //
GLOBENEWSWIRE
